Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # Hoffmann-La Roche
  • # FDA Approval
  • # Diabetes
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Positive Outcomes From the Initial Prenatal Therapy for Spinal Muscular Atrophy

20 February 2025

A study revealed that metastatic cancers in mice can be cured by a plant virus treatment

18 May 2024

The Two Proteins Involved in Alzheimer’s Disease Have Distinct Effects on Brain Circuitry

7 February 2025

Researchers found the impact on hormone levels in mice by gut microbiome

30 September 2024

Amgen’s Imdelltra® (tarlatamab-dlle) Significantly Reduces Risk of Death by 40% in Small Cell Lung Cancer Phase 3 Trial

2 June 2025

Prostate cancer can be detected by a urine test

24 April 2024

AstraZeneca’s Imfinzi Gains EU Approval as First Perioperative Immunotherapy for High-Risk Bladder Cancer

4 July 2025

Blood Markers can detect rare forms of dementia and neurological diseases

19 June 2024

Activity-driven brain wiring even during early embryonic development

19 August 2024

Scientists map the human brain’s networks regulating the gene function

27 May 2024

Researchers discovered a new code supporting the gene activity

21 August 2024

Harmful immune responses can be prevented by redesigning future mRNA-based therapeutics – Research

17 December 2023

Myeloma

Johnson & Johnson’s DARZALEX FASPRO® Regimen Shows 95% 4-Year Progression-Free Survival in Newly Diagnosed Myeloma Patients
Clinical Trials Healthcare & Pharmaceuticals News

Johnson & Johnson’s DARZALEX FASPRO® Regimen Shows 95% 4-Year Progression-Free Survival in Newly Diagnosed Myeloma Patients

Athulya B S 3 June 2025

Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.

European Medicines Agency Panel Recommends Blenrep Combinations for Multiple Myeloma
Cancer Clinical Trials Regulatory

European Medicines Agency Panel Recommends Blenrep Combinations for Multiple Myeloma

Ajmal Aseem 24 May 2025

GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.

FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma
Cancer Healthcare & Pharmaceuticals News Regulatory

FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma

Athulya B S 22 May 2025

Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.

GSK’s Blenrep Combinations Approved in Japan for Relapsed or Refractory Multiple Myeloma
Healthcare & Pharmaceuticals News Regulatory Approval

GSK’s Blenrep Combinations Approved in Japan for Relapsed or Refractory Multiple Myeloma

Ajmal Aseem 20 May 2025

GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.

CellCentric Secures $120 Million Investment to Develop Oral Myeloma Drug Inobrodib
Business Cancer Healthcare & Pharmaceuticals

CellCentric Secures $120 Million Investment to Develop Oral Myeloma Drug Inobrodib

Athulya B S 19 May 2025

CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Cytiva Hiring a Quality Control Technician in Cardiff, United Kingdom
  • PhD Position in Dialysis Therapy – University of Twente, Netherlands
  • Eli Lilly and Company Hiring a Analytical Technical Steward-Peptides in Hyderabad, India – June, 2025
  • ICON Hiring a Clinical Data Programming Lead in Chennai, India
  • PhD Position in Food Biotechnology – University of Reading, United Kingdom
SciRealityPress BiotechReality

A SciRealityPress Associate

DMCA.com Protection Status

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy